CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA by Ugo Testa, Elvira Pelosi, Germana Castelli

“… Multiple myeloma (MM), characterized by abnormal proliferation of clonal plasma cells, is an incurable hematological malignancy. Various immunotherapy strategies have emerged as an efficacious approach for the treatment of MM, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cells. …”
Get full text

Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies by Chenyun Zhang, Haizhou Liu

“…In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. In the meantime, various preclinical and clinical studies have extensively explored dual-target CAR-T therapies which can be designed to recognize two antigens simultaneously based on the immunophenotype of tumor cells. …”
Get full text

Severe Hemolytic Anemia Associated with Mild Pneumonia Caused by Mycoplasma pneumonia by Zafer Kurugol, Serife Sebnem Onen, Guldane Koturoglu

“…As the erythrocyte sedimentation rate was excessively elevated, the differential diagnosis primarily comprised hematological malignancies. Direct Coombs' test was positive. …”
Get full text

A pivotal decade for bispecific antibodies? by Marlena Surowka, Christian Klein

“…In the 2020s, the approval of additional bsAbs can be expected in hematological malignancies, solid tumors and non-oncology indications, establishing bsAbs as essential part of the therapeutic armamentarium.…”
Get full text

Chromothripsis in Treatment Resistance in Multiple Myeloma by Kyoung Joo Lee, Ki Hong Lee, Kyong-Ah Yoon, Ji Yeon Sohn, Eunyoung Lee, Hyewon Lee, Hyeon-Seok Eom, Sun-Young Kong

Get full text

Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP by Min Kyeong Kim, Kyong-Ah Yoon, Eun Young Park, Jungnam Joo, Eun Young Lee, Hyeon-Seok Eom, Sun-Young Kong

Get full text

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment by Rahul Navab, Pragyat Futela, Verkha Kumari, Jayesh Valecha, Ramansh Bandhu Gupta, Rohit Jain

“…Multiple Myeloma (MM) is a hematologic malignancy characterized by clonal plasma cell development, leading to serious complications. …”
Get full text

An Adult Patient with Systemic Mastocytosis and B-Acute Lymphoblastic Leukemia by Theodoros Iliakis, Niki Rougkala, Panagiotis T. Diamantopoulos, Vasiliki Papadopoulou, Fani Kalala, Konstantinos Zervakis, Nefeli Giannakopoulou, Polixeni Chatzinikolaou, Georgia Levidou, Eleftheria Lakiotaki, Penelope Korkolopoulou, Efstratios Patsouris, Eleni Variami, Nora-Athina Viniou

“…In a significant proportion of patients, systemic mastocytosis (SM) coexists with another hematologic malignancy, termed systemic mastocytosis with an associated hematologic nonmast cell lineage disorder (SM-AHNMD). …”
Get full text

Models for the marrow: A comprehensive review of AI‐based cell classification methods and malignancy detection in bone marrow aspirate smears by Tabita Ghete, Farina Kock, Martina Pontones, David Pfrang, Max Westphal, Henning Höfener, Markus Metzler

“…This review presents a systematic analysis of models for cell classification and detection of hematological malignancies published in the last 5 years (2019–2024). …”
Get full text

The Dual Role of HLA-G in Cancer by Nathalie Rouas-Freiss, Philippe Moreau, Joel LeMaoult, Edgardo D. Carosella

“…We here review the current data on the role of HLA-G in cancer based on recent findings of an unexpected antitumor activity of HLA-G in hematological malignancies. For the past decade, HLA-G has been described as a tumor-escape mechanism favoring cancer progression, and blocking strategies have been proposed to counteract it. …”
Get full text

Hypercalcemia, Anemia, and Acute Kidney Injury: A Rare Presentation of Sarcoidosis by Neeraj Sharma, Hassan Tariq, Kalpana Uday, Yevgeniy Skaradinskiy, Masooma Niazi, Sridhar Chilimuri

“…Our Initial impression was likely underlying hematologic malignancy such as lymphoma or multiple myeloma. …”
Get full text

Exosomal lncRNAs as diagnostic and therapeutic targets in multiple myeloma by Hong Yan, Nan Jiang, Xiaoying Li, Chenyang Lin, Fang Wang, Juan Zhang, Lijuan Chen, Dan Li

“…Multiple Myeloma (MM) is the second most common malignancy of the hematopoietic system, accounting for approximately 10% of all hematological malignancies, and currently, there is no complete cure. …”
Get full text

Clinical Features and Outcome of Mucormycosis by Carlos Rodrigo Camara-Lemarroy, Emmanuel Irineo González-Moreno, René Rodríguez-Gutiérrez, Erick Joel Rendón-Ramírez, Ana Sofía Ayala-Cortés, Martha Lizeth Fraga-Hernández, Laura García-Labastida, Dionicio Ángel Galarza-Delgado

“…Ten patients had diabetes mellitus as the underlying disease, and 6 patients had a hematological malignancy (acute leukemia). Of the diabetic patients, 3 had chronic renal failure and 4 presented with diabetic ketoacidosis. …”
Get full text

Disseminated nocardiosis in a patient with AIDS and B-cell non-Hodgkin’s lymphoma: a case report by Delvis R. Reverón, David M. Flora-Noda, Lily M. Soto, Maribel Dolande, Juan Frey, Aleiram Chaurio, Bárbara D. Ruiz-Alayón, Jocays Caldera, Fhabián S. Carrión-Nessi, David A. Forero-Peña

“…Abstract Background Disseminated nocardiosis is a rare and potentially fatal disease, with a higher incidence in immunocompromised patients, such as those living with human immunodeficiency virus (HIV) or hematological malignancies, including lymphoma. Information on Nocardia spp. infection in Venezuela is limited. …”
Get full text

In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead? by Carlotta Mattioda, Claudia Voena, Gianluca Ciardelli, Clara Mattu

“…This review aims at reporting an updated overview of state-of-the-art hematological malignancies 3D in vitro models, emphasizing the key features and limitations of existing systems to inspire further research in this underexplored field.…”
Get full text

Donor lymphocyte infusions: An experience from a tertiary care center of North India by Divjot Singh Lamba, Parmatma Prasad Tripathi, Rekha Hans, Alka Khadwal, Ratti Ram Sharma

“…However, further evidence is required to evaluate its efficacy, especially in relapsed or residual hematological malignancies.…”
Get full text

MicroRNAs as Haematopoiesis Regulators by Ram Babu Undi, Ravinder Kandi, Ravi Kumar Gutti

“…Aberrant expression of miRNAs was observed in hematological malignancies including chronic myelogenous leukemia, chronic lymphocytic leukemia, multiple myelomas, and B cell lymphomas. …”
Get full text

Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity by Nilberto Dias de Araújo, Fábio Magalhães Gama, Mateus de Souza Barros, Thaís Lohana Pereira Ribeiro, Fabíola Silva Alves, Lilyane Amorim Xabregas, Andréa Monteiro Tarragô, Adriana Malheiro, Allyson Guimarães Costa

“…In recent years, these cell populations have been associated with a repertoire of anti- or protumor responses and play important roles in the dynamics of solid tumors and hematological malignancies, thus, encouraging the development of new investigations in the area. …”
Get full text

The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors by Salvatrice Mancuso, Vincenzo Accurso, Marco Santoro, Simona Raso, Angelo Davide Contrino, Alessandro Perez, Florinda Di Piazza, Ada Maria Florena, Antonio Russo, Sergio Siragusa

“…Essential thrombocythemia is a rare hematological malignancy with good overall survival, but moderate to high risk of developing arterial or venous thrombosis lifelong. …”
Get full text

Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications by Shaimaa Khattab, Adriatik Berisha, Natalia Baran, Pier Paolo Piccaluga

“…Acute myeloid leukemias (AMLs) comprise a group of genetically heterogeneous hematological malignancies that result in the abnormal growth of leukemic cells and halt the maturation process of normal hematopoietic stem cells. …”
Get full text